awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34781970-93868763-5699-479D-B5C0-6EA86A370F56
Q34781970-93868763-5699-479D-B5C0-6EA86A370F56
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34781970-93868763-5699-479D-B5C0-6EA86A370F56
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer
P2860
Q34781970-93868763-5699-479D-B5C0-6EA86A370F56
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34781970-93868763-5699-479D-B5C0-6EA86A370F56
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
729f94d29fa20851d2e8109c3832c2f39da41010
P2860
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.